Search results
Results from the WOW.Com Content Network
Cardiologist Helen B. Taussig learned of the damaging effects of the drug thalidomide on newborns and in 1967, testified before Congress on this matter after a trip to Germany where she worked with infants with phocomelia (severe limb deformities). As a result of her efforts, thalidomide was banned in the United States and Europe. [46]
Thalidomide is racemic; while S-thalidomide is the bioactive form of the molecule, the individual enantiomers can racemize to each other due to the acidic hydrogen at the chiral centre, which is the carbon of the glutarimide ring bonded to the phthalimide substituent. The racemization process can occur in vivo.
Additionally, informed consent became a participation requirement and rules were put into place. This regulation was influenced by the results of 1950 use of thalidomide in Western Europe for pregnant women. They were prescribed the sedative thalidomide, which was inaccurately marketed as a morning sickness treatment. Women gave birth to more ...
Hagens Berman Adds Five Cases to Thalidomide Litigation Firm now represents 49 alleged victims in case against drug manufacturer, others, citing new evidence SEATTLE--(BUSINESS WIRE)-- Hagens ...
Thalidomide, developed by the German firm Gruenenthal, killed an estimated 80,000 children around the world before they were born, and 20,000 more were born with defects.
Survivors of the harmful morning sickness drug thalidomide were in the public gallery Wednesday when Australia’s Parliament made a national apology to them on the 62nd anniversary of the drug ...
France, Germany, European Union Polyneuropathy. [3] Natalizumab (Tysabri) 2005–2006 US Voluntarily withdrawn from US market because of risk of Progressive multifocal leukoencephalopathy (PML). Returned to market July 2006. Nefazodone: 2004 Europe, Australia, New Zealand and Canada [35] [36] [37]
Frances Kathleen Oldham Kelsey CM (née Oldham; July 24, 1914 – August 7, 2015) was a Canadian-American [1] pharmacologist and physician. As a reviewer for the U.S. Food and Drug Administration (FDA), she refused to authorize thalidomide for market because she had concerns about the lack of evidence regarding the drug's safety. [2]